Merck KGaA Articles
Merck Serono spins out sixth company - Calypso Biotech - to focus on gastrointestinal immunological disorders
5 March 2013
Merck Serono to in-license Opexa's MS drug candidate Tcelna
6 February 2013
Merck Serono initiation of TH-302 Ph III trial triggers $30 million milestone for Threshold
29 January 2013
US FDA approves Merck KGaA's Rebif Rebidose
4 January 2013
Merck Serono collaborates with Neopharma for production in UAE
4 December 2012
Citi upbeat on Vectura; S&P's upgrades Merck KGaA
2 December 2012
Big Pharma doing more for access to medicine in developing countries than two years ago
28 November 2012
Merck KGaA third-quarter sales and earnings beat forecasts
15 November 2012
News briefs from Threshold, Merck KGaA and GSK
18 September 2012
Merck Serono gains rights to Ph II cancer drug from Symphogen for up to 475 million euros
6 September 2012
Merck KGaA to slash German workforce by around 10%
5 September 2012
Merck Serono creates second company under EPP
3 September 2012
Merck KGaA acquires cell culture media specialist Biochrom
22 August 2012
Merck KGaA posts strong 11.6% second-quarter sales growth
14 August 2012
Merck Serono sets up Prexton Therapeutics as first spin-off from its Entrepreneur Partnership Program
31 July 2012
News briefs from Merck KGaA and Sanofi
5 July 2012
New public-private partnership to develop a treatment for schistosomiasis-infected pre-school children
2 July 2012
Merck KGaA to rationalize operations in Switzerland
24 April 2012
News briefs on Janssen, Bayer and Merck KGaA/Threshold
12 April 2012
Merck KGaA licenses pancreatic cancer drug from Threshold
6 February 2012
Expanded use for Merck Serono’s Rebif in EU
25 January 2012
Ablynx earns milestone from Merck Serono
13 December 2011
Executive appointments at Merck KGaA and Pharmalink
15 November 2011
Merck Serono expands osteoarthritis collaboration with Ablynx
9 November 2011
Merck Serono and Ono Pharma collaborate on investigational oral MS drug and cancer vaccine
4 October 2011
Merck KGaA has another stab at multiple sclerosis, gaining rights to Peptimmune PI-2301 program
19 September 2011
F-Star and Merck Serono in up to 492 million-euro collaboration on novel targeted biologics
9 September 2011
UK’s NICE negative draft guidance for metastatic colorectal cancer drugs Erbitux, Avastin and Vectibix
6 September 2011
Erbitux and Gilenya added to Australia’s PBS listing
2 September 2011
CV events halt Sanofi Multaq trial; Merck KGaA drops Idera cancer drug on safety concerns
8 July 2011
Merck Serono strengthens executive team; ProStrakan names new CEO; Sanofi Pasteur MSD gets new president
8 July 2011
Merck Serono in deal with Affectis Pharma to develop oral neurodegenerative disease drugs
8 June 2011
Investment in oncology drug development remains strong, with 133 firm initiating late-stage trials
3 June 2011
Merck KGaA US units agree $44.3 million settlement with DoJ; Ranbaxy faces up to $1 billion fine?
5 May 2011
Merck KGaA 1st-qtr 2011 net profit income rockets 77%
29 April 2011
Merck KGaA strengthens research cooperation with Israel; files for Erbitux indication extension
31 March 2011
Merck KGaA acquires microbiology business of Biotest AG
23 March 2011
Merck Serono pulls European application for oral MS drug Movectro; Sun withdraws topotecan
18 February 2011
Apeiron gets rights to Merck KGaA Ph II cancer biologics
2 February 2011
EMA advisory committee backs Gilenya, Halaven, Jevtana, Pravafenix and Trobalt, but negatives for Fampyra and Multaq
24 January 2011
Merck Serono says Erbitux long-term survival benefit for mCRC patients confirmed with FOLFOX
19 January 2011
Merck Serono in up to 134 million-euro deal with Domain Thera for Parkinson’s disease drug targets
17 January 2011
Mylan subsidiary Dey Pharma settles $280 million with US DoJ, but Merck KGaA to pay
22 December 2010
Sanofi-Aventis in $800 million deal with Avila; links up with Merck KGaA and with Oxford University for cancer research
20 December 2010
Merck KGaA replaces Schnee; Sanofi-Aventis makes senior executive change and extends Genzyme tender offer
13 December 2010
Attitudes of US relapsing-remitting multiple sclerosis patients to current and emerging therapies
6 December 2010
Merck Serono’s ready-to-use formulation of Saizen recommended for approval in Europe
16 November 2010
US FDA approves Merck KGaA Egrifta to treat lipodystrophy in HIV patients and development plan for Bionovo’s Menerba
11 November 2010
Merck KGaA sells women’s health business to Teva in $368 million-euro deal; Hikma buys Baxter’s injectable business for $112 million
29 October 2010
Strong cancer drug results presented by Roche, Sanofi-Aventis, Merck KGaA, Amgen and Eisai at ESMO Congress
12 October 2010
AstraZeneca gets EU backing for OA/RA drug Vimovo; Merck KGaA appeals EMEA decision on cladribine for MS
11 October 2010
Europe’s CHMP gives negative opinion for Merck KGaA’ cladribine in multiple sclerosis; backs Sanofi Pasteur MSD’s RotaTeq and GSK’s Rotarix
24 September 2010
Novartis gains FDA approval for Gilenya, first oral MS drug cleared in USA; says SOM230 effective against Cushing’s disease
22 September 2010
Novartis gets Russian approval for oral MS drug Gilenya (fimgolimid)
13 September 2010
Medicines Australia agreement to reduce Rx drug prices; Merck Serono’s Erbitux funding under PBS recommended
23 August 2010
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
